Top 30 Stocks: AAPL, MCD, GOOGL, NVDA, AMZN, META, AVGO, UNH, LLY, COST, HD, NKE, MSFT, LIN, ADBE, V, MA, MRK, TMO, JNJ, WMT, PGR, CRM, TSLA, SCHW, PEP, ORCL, PG, JPM, SPGI

Certainly! Here’s an example of a model portfolio using your stock universe, normalized to sum to 1.00. I’ll also explain the underlying strategy, allocation logic, and commentary on potential outperformance relative to the S&P 500.

---
### **Model Portfolio: Stock Weights**

| Stock   | Ticker | Weight  |
|---------|--------|---------|
| Apple           | AAPL  | 0.06    |
| Microsoft       | MSFT  | 0.06    |
| Alphabet        | GOOGL | 0.06    |
| Nvidia          | NVDA  | 0.07    |
| Amazon          | AMZN  | 0.06    |
| Meta            | META  | 0.06    |
| Broadcom        | AVGO  | 0.05    |
| UnitedHealth    | UNH   | 0.03    |
| Eli Lilly       | LLY   | 0.05    |
| Costco          | COST  | 0.04    |
| Home Depot      | HD    | 0.03    |
| Nike            | NKE   | 0.02    |
| Linde           | LIN   | 0.02    |
| Adobe           | ADBE  | 0.04    |
| Visa            | V     | 0.03    |
| Mastercard      | MA    | 0.03    |
| Merck           | MRK   | 0.02    |
| Thermo Fisher   | TMO   | 0.03    |
| Johnson&Johnson | JNJ   | 0.03    |
| Walmart         | WMT   | 0.04    |
| Progressive     | PGR   | 0.02    |
| Salesforce      | CRM   | 0.03    |
| Tesla           | TSLA  | 0.04    |
| Charles Schwab  | SCHW  | 0.02    |
| PepsiCo         | PEP   | 0.03    |
| Oracle          | ORCL  | 0.03    |
| Procter&Gamble  | PG    | 0.03    |
| JPMorgan Chase  | JPM   | 0.03    |
| S&P Global      | SPGI  | 0.02    |

**Sum: 1.00**

---
## **Strategy & Logic**

### 1. **Growth Tilt with Risk Awareness**
- Overweight leading large-cap tech/growth companies (AAPL, MSFT, GOOGL, NVDA, AMZN, META, AVGO) where secular trends in AI/cloud/digital consumption are likely to persist.
- NVDA receives the highest weight (0.07) for its AI hardware/datacenter leverage, but single-stock risk is capped.

### 2. **Diversification Across Sectors**
- Not all weight goes to Big Tech: add healthcare (LLY, UNH, JNJ, MRK, TMO), consumer staples (PG, PEP, WMT, COST), discretionary (NKE, TSLA, HD).
- Financials (JPM, SPGI, SCHW, V, MA) & industrials/materials (LIN) provide balance and reduce volatility.

### 3. **Quality & Moat Emphasis**
- Focused on companies with sustainable competitive advantages, strong balance sheets, high margins, network effects, or essential consumer demand.

### 4. **Risk Moderation**
- While sector weights differ from the S&P 500, no individual stock is above ~7%. 
- Defensive stocks offset cyclical/growth exposure (PG, PEP, JNJ, WMT).

### 5. **Avoid Overcrowding**
- Some names (like NVDA, AAPL, MSFT) are overweight versus their S&P weight but not so much as to create “megacap risk.” Allocations to defensive, healthcare, and consumer names act as volatility dampeners.

---

## **Commentary/Rationale**

- **Potential to Outperform:** This portfolio deliberately *leans into dominant growth franchises* (Tech/AI/Cloud) more than the S&P 500, which is overall more market cap weighted and diversified. Meanwhile, it keeps a floor of defensives (healthcare, staples, insurance), which has shown resilience in bear markets.
- **Balanced Growth & Stability:** The model accounts for future upside from innovation and secular trends, yet seeks to avoid excessive single-stock or sector risk.
- **Market Context:** Allocations are suitable for a market where AI/cloud/growth is still a tailwind, but macro/policy risks exist—hence inclusion/weighting of staples and drugmakers.
- **Flexibility:** Portfolio could be rebalanced based on valuation, momentum, or macro outlook changes, but starts with these overweight and underweight selections for near/intermediate-term outperformance potential.

---

**Summary of Strategy:**  
**“QG+GARP (Quality-Growth plus Growth-at-a-Reasonable-Price):** Overweighting dominant global platforms and moaty, innovative companies; holding sufficient sector diversification and defensives—thus, more ‘active’ and growth-tilted versus the S&P500 for a shot at outperformance with reasonable risk controls.”

---

**Note:** This is a hypothetical example, not investment advice. Investor goals, risk tolerance, tax, and time-horizon must be considered before actual implementation. Periodic rebalancing and monitoring are recommended.